ReviewCureus2026
Tranexamic Acid in the Management of Hemoptysis: Pharmacology, Administration Routes, Clinical Evidence, and Practical Considerations.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemoptysis is a frequent and potentially life-threatening pulmonary presentation that requires rapid stabilization and timely definitive management. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, has gained increasing interest as an adjunctive medical therapy for hemoptysis, supported by recent randomized trials, observational studies, and systematic reviews evaluating inhalational and endobronchial routes. While bronchoscopy, bronchial artery embolization (BAE), and surgery remain central to the management of severe or life-threatening hemoptysis, TXA may reduce bleeding burden, shorten hospitalization, and serve as a temporizing or bridging therapy while definitive interventions are arranged. This narrative review summarizes TXA pharmacology, available routes of administration, dosing strategies, clinical evidence, safety considerations, and practical integration into contemporary hemoptysis management pathways. The literature selection approach is briefly described in the manuscript body to improve transparency regarding how representative studies were identified and prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.